Literature DB >> 10347329

CA 125 and its relation to cardiac function.

H Nägele1, M Bahlo, R Klapdor, D Schaeperkoetter, W Rödiger.   

Abstract

BACKGROUND: CA 125, known as a marker for ovarian cancer with hypothetical but hitherto uncharacterized biologic functions, was reported to be elevated in some not-well-defined benign conditions. There are no reports on fluctuations of CA 125 related to cardiac function, especially the failing heart and neurohumoral factors such as norepinephrine or atrial natriuretic peptid/e. METHODS AND
RESULTS: CA 125 blood levels were determined in patients with heart failure before and after heart transplantation (HTx). In 71 patients, parallel determinations of norepinephrine, atrial natriuretic peptide, pulmonary capillary wedge pressure, and right atrial filling pressure were done. CA 125 levels also were prospectively studied in patients with heart failure with stabilization (n = 25) or worsening of the clinical status (n = 9) and after HTx (n = 25). Parallel determinations of the tumor markers CEA, CA 199, CA 153, TPS, and TPA were also done. The results were grouped according to the clinical status (New York Heart Association class) of the patients. CA 125 was significantly correlated with neurohormones and filling pressures. Follow-up investigations revealed a decrease of CA 125 levels after HTx (401 +/- 259 U/L vs 33 +/- 22 U/L, P <.001, n = 25) or stabilization (429 +/- 188 U/L vs 78 +/- 35 U/L, P <.001, n = 25) and an increase during worsening of heart failure (42 +/- 25 U/L vs 89 +/- 32 U/L, P <.01, n = 9). In 4 patients after HTx, unexpected death was preceded by rising CA 125 levels. CEA, CA 199, CA 153, TPS, or TPA did not correlate with heart failure status or clinical events.
CONCLUSIONS: CA 125 is a marker of the clinical and hemodynamic status and the course of patients with heart failure before and after heart transplantation. The determination of CA 125 serum levels may be an additional tool in the management of these patients. In patients with cancer, these "nonspecific" changes must be considered when CA 125 levels are determined. Whether CA 125 has a specific biologic role in heart failure deserves further studies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10347329     DOI: 10.1016/s0002-8703(99)70360-1

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  22 in total

Review 1.  Clinical utility of antigen carbohydrate 125 in heart failure.

Authors:  Julio Núñez; Gema Miñana; Eduardo Núñez; Francisco J Chorro; Vicent Bodí; Juan Sanchis
Journal:  Heart Fail Rev       Date:  2014-09       Impact factor: 4.214

2.  Normalization of cancer antigen 125 after mitral valve replacement in a patient with congestive heart failure due to mitral valve endocarditis.

Authors:  Hiroki Sugishita; Hiroshi Imagawa; Kanji Kawachi; Shinnji Takano; Nobuhiro Tsunooka; Fumiaki Shikata
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2005-09

3.  Carbohydrate antigen-125 is a mirror of both left and right sides of the heart.

Authors:  Taner Sen; Tolga Aksu; Mehmet Birhan Yilmaz
Journal:  Tex Heart Inst J       Date:  2012

4.  Factors associated with the development of atrial fibrillation in patients with rheumatic mitral stenosis.

Authors:  Mehmet Ozaydin; Yasin Turker; Ercan Varol; Sule Alaca; Dogan Erdogan; Nigar Yilmaz; Abdullah Dogan
Journal:  Int J Cardiovasc Imaging       Date:  2010-03-24       Impact factor: 2.357

5.  Carbohydrate antigen-125 and N-terminal pro-brain natriuretic peptide levels: compared in heart-failure prognostication.

Authors:  Serkan Ordu; Hakan Ozhan; Recai Alemdar; Mesut Aydin; Onur Caglar; Hatice Yuksel; Hayati Kandis
Journal:  Tex Heart Inst J       Date:  2012

Review 6.  Novel and potential future biomarkers for assessment of the severity and prognosis of chronic heart failure : a clinical review.

Authors:  David R Buvat de Virginy
Journal:  Heart Fail Rev       Date:  2006-12       Impact factor: 4.214

7.  Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum.

Authors:  Daniel Gilbert Weber; Georg Johnen; Dirk Taeger; Anne Weber; Isabelle Mercedes Gross; Beate Pesch; Thomas Kraus; Thomas Brüning; Monika Gube
Journal:  Biomark Insights       Date:  2010-01-28

8.  Elevated carbohydrate antigen 125 levels in hypertrophic cardiomyopathy patients with heart failure.

Authors:  Ercan Varol; Mehmet Ozaydin; Ahmet Altinbas; Suleyman M Aslan; Abdullah Dogan; Ozkan Dede
Journal:  Heart Vessels       Date:  2007-01-26       Impact factor: 2.037

9.  Elevated CA 125 and ascites: not always malignancy.

Authors:  C J Lockhart; G E McVeigh; M T Harbinson
Journal:  Ir J Med Sci       Date:  2007-07-28       Impact factor: 1.568

10.  Clinical and prognostic value of elevated CA125 levels in patients with coronary heart disease.

Authors:  X Rong; Z Yunke; L Guoping; C Zhenyue
Journal:  Herz       Date:  2014-05-17       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.